Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Picosulfuric acid | The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Efrotomycin. |
| BCG vaccine | The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Efrotomycin. |
| Typhoid vaccine | The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Efrotomycin. |
| Dicoumarol | The risk or severity of bleeding can be increased when Efrotomycin is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Efrotomycin is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Efrotomycin is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Efrotomycin is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Efrotomycin is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Efrotomycin is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Efrotomycin is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Efrotomycin is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Efrotomycin is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Efrotomycin is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Efrotomycin is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Efrotomycin is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Efrotomycin is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Efrotomycin is combined with (S)-Warfarin. |
| Lactulose | The therapeutic efficacy of Lactulose can be decreased when used in combination with Efrotomycin. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Efrotomycin. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Efrotomycin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Quinisocaine. |
| Cisatracurium | Efrotomycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Efrotomycin is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Efrotomycin. |